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2 Abbreviations 
ADR Adverse drug reaction 
APC Antigen presenting cell 
BAT Basophil activation test 
CS Chondroitin sulphate 
ELISA Enzyme-linked immunosorbent assay 
FDE Fixed drug eruption 
GAG Glycosaminoglycan 
IFN Interferon 
IL Interleukin 
LMWH Low molecular weight heparin 
LTT Lymphocyte transformation test 
MHC Major Histokompatibility Complex 
MPE Maculopapular exanthema 
NK Natural killer cell 
OD Optical densitiy 
OSCS Oversulphated chondroitin sulphate 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
PHA Phytohemagglutinin 
ROC Receiver operating characteristics 
SJS Stevens-Johnson syndrome 
TCR T cell receptor 
TEN Toxic epidermal necrolysis 
UFH Unfractionated heparin 
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3 Introduction 
3.1 T cell mediated immunity 
Bone marrow derived precursor cells reach the thymus via the bloodstream. At this point in 
time they neither express CD4 and CD8 (Co-receptors of the T cell receptor), nor CD3 (part 
of the T cell receptor) or the T cell receptor. During proliferation in the lymph node somatic 
recombination occurs. Subsequently the cells express CD4 and CD8 and are called double 
positive cells. T cell maturation contains two selection processes: 
i)  Positive selection 
Positive selection involves a physical interaction between immature thymocytes and 
epithelial cells in the thymic cortex. Cells that bind to cortical, thymic epithelial cells, 
survive. Expression of non-binding receptor is suppressed. 
ii)  Negative selection 
Selection of single positive thymocytes occurs at dendritic cells. Thymocytes with 
high affinity to their cognate Major Histokompatibility Complex (MHC)-molecule 
bind to a self-peptide. 
The cells mature in the thymus. The T cell receptor recognises potential antigen 
peptide associated with MHC-I and MHC-II, respectively (1). 
3.1.1 Antigen cognition 
Peptides are presented by MHC. T cells need these receptors to recognise the antigen  
(Figure 1). MHC is differentiated into two classes: 
i)  MHC-I 
Displays several cell information about interior to T Killer cells. 
ii)  MHC-II 
MHC-II are positioned on antigen presenting cells (APC). They present proteins to T  
cells. 
Both molecules look very similar. A class I MHC molecule is made up of one long 
chain (heavy chain) plus a short chain (b2-microglobulin), and class II has two long 
chains (a and b). 
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Figure 1. Comparison of MHC I and MHC II molecules 
 
For class I MHC the protein fragment must be about nine amino acids in lenght to fit in 
properly. Class II molecules are slightly different: the ends of the groove are open, so protein 
fragments as large as about fifteen amino acids fit in (2, 3). 
3.1.2 T cell activation 
The first step in the activation of a helper T cell is the recognition of its cognate antigen (e.g. 
a fragment of a bacterial protein) displayed by class II MHC molecules on the surface of an 
antigen presenting cell. A second signal is required for activation. This second signal is non-
specific, and it involves a protein (B7 in Figure 2) on the surface of an antigen presenting cell 
that plugs into its receptor on the surface of the helper T cell (CD28 in Figure 2). 
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Figure 2. T cell activation 
 
Activated T cells synthesise the cytokine IL-2 and an IL-2 receptor with high affinity which 
results to interaction induced clonal expansion and the following differentiation of T cells. A 
resulted Teffector cell does not need any further co-stimulation to be stimulated. 
 
Naive T cells can be activated in different ways. They can be stimulated by strong APC and 
high level of B7 or they need additional help by activated CD4+ T cells. CD4+ cells activate 
CD8+ T cells either by secreted IL-2 or indirect by B7 on APC. 
Naive cells that recognise antigens in the absence of co-stimulating signals, get anergic and 
cannot be stimulated further (3-5). 
3.1.3 Activation of armed effector T cells 
T cell effector functions are mediated by a broad spectrum of effector molecules. 
Cytotoxic effector T cells eliminate target T cells by secretion of cytotoxins like perforin and 
granzyme stored in lytic granula. Apoptosis is induced following secretion. 
T effector cell molecules are cytokines: glycoproteins that are secreted transiently and not 
stored inside of cells. They have a short half life and are efficient on short distances. 
Cytokines are soluble and membrane bond signalling molecules and are divided into 
interleukins, tumor necrosis factors, interferons and chemokines. 
Cytokines control both the intensity and type of immune response mounted by 
stimulating/suppressing the different cells involved in an immune response. Although each 
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Macrophage 
Helper 
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cytokine exerts a specific effect on the target cell, they rarely act alone. Usually, the target cell 
is exposed to many cytokines that have synergistic, antagonistic, or redundant effects (6). 
 
When virgin helper T cells are first activated, the major cytokine they secrete is IL-2. Once 
TH cells have proliferated to build up a clone of identical cells, they may be restimulated by 
an APC, and begin to secrete other cytokines such as interferon (IFN)-g, interleukin (IL)-4, 
IL-5, IL-10, and TNF. 
 
In this context, two typical TH1 and two typical TH2 cytokines were depicted. Important 
cytokines produced by TH1 cells are IL-2 and IFN-g. Important effector molecules produced 
by TH2 cells are IL-5 and IL-10 (Figure 3)(7). 
 
 
 
Figure 3. TH1 and TH2 cytokines  
 
Generally, a single TH cell does not secrete all these different cytokines. In fact, TH cells tend 
to secrete subsets of the possible cytokines. These subsets frequently are of two general types: 
TH1 and TH2. 
 
Clearly, there are TH cells which secrete mixtures of cytokines that do not conform to TH1/ 
TH2 paradigm, but the concept of TH1 and TH2 subsets turned out to be useful in trying to 
make sense of the mixture of cytokines (the cytokine pattern) that TH cells produce (8-11). 
3.1.4 IL-5 
IL-5 is produced by TH2 cells and mast cells. Stimulation of B-cell growth and increase of 
immunoglobulins are functions of IL-5. IL-5 has a key function in eosinophil activation. It 
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consists of 115 amino acids and is part of the hematopetic family. A long time IL-5 was 
associated with different allergic diseases, e.g. allergic rhinitis and asthma. Due to high 
accordance with the pathophysiology of asthma, IL-5 was imputed to play an important role 
in the pathophysiology of these diseases (12). 
3.1.5 IFN-g 
IFN-g is essentially produced by activated CD8+ und CD4+ TH1 T cells and natural  
killer cells (NK). IFN-g has antiviral and antiparasital characteristics and has inhibitory effects 
on proliferation of endothelial cells, smooth muscle cells hematopoietic precursor cells and 
tumor cells. IFN-g promotes proliferation of Tcytotoxic cells and their reactivity on other 
cytokines. It stimulates activation of NK cells, macrophages and fibroblasts and supports their 
activity. Furthermore it inhibits cytokine production of TH2 cells. In addition it induces cell 
surface molecules and receptors, e.g. IL-2 receptor and class II MHC molecules on T cells 
fibroblasts and tumor cells (12). 
3.1.6 IL-2 
In principle IL-2 is an essential factor for development and regulation of the effective immune 
response. IL-2 regulates the cytotoxic response in a positive way and the regulatory response 
in a negative way. IL-2 activated T cells promote the growth of lymphocyte component. In 
terms of positive feedback mechanism IL-2 induces the expression of own IL-2 receptors. IL-
2 is important for maintaining Tregulatory cell function (12). 
Although induction of FoxP3 and IL-2 stimulation is well investigated the results are 
controversial due to different test conditions. Some aspects have to be considered: 
i) Generation of Tregulatory 
ii) Function of Tsuppressor (regulatory) cells in vivo and in vitro 
iii) Interaction between Teffector and Tregulatory cells 
iv) feedback loops 
3.1.7 IL-10 
IL-10 plays an essential role in regulation of inflammatoric processes and inhibits allergic and 
autoimmune reactions. It is produced by TH2 cells, monocytes, macrophages and dendritic 
cells and can also be produced by regulatory CD4+ T cells, CD8+ T cells and NK T cells. 
Inhibitory effects are related to antimicrobial effector functions, production of pro 
inflammatoric cytokines, differentiation and immune stimulatoric functions of dendritic cells, 
T cell proliferation and expression of adhesion molecules of leukocytes. IL-10 inhibits the 
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differentiation and activation of TH1 cells and concomitantly synthesis of IL-12, IFN-g and 
TNF. Furthermore it inhibits activation and also accessory and antigen presenting functions of 
macrophages by e.g. reduction of class II MHC expression and inhibition of production and 
function of membrane bond co-stimulatory for T cell- and NK cell activation and therefore it 
inhibits monocyte/macrophage-mediated antigen stimulated cytokine production and 
proliferation of T cells and NK cells (13). 
3.1.8 Generation of T memory cells 
During a typical acute infection, the induction of adaptive immune response follows a quick 
and strong expansion with differentiation of antigen specific T cells. 
After elimination of the infection, the effector T cells are removed so that natural conditions 
are reconstituted again. This procedure is induced apoptosis mediated. 
Thereupon, protective immunity with an immunologic memory mediated by clonal expanded 
antigen specific lymphocytes (memory cells) occurs. 
The mechanism of the generation of memory T cells occurs is still unclear. Some differation 
scheme exist. According to a classic scheme (“linear differentiation model“) memory T cells 
develop from a small population of antigen specific T cells that are spared from apoptosis. 
An alternative scheme (“decreasing potential hypothesis“) describes a differentiation of 
memory T cells that is influenced by intensity and duration of the stimulation. According to 
this alternative a permanent stimulation promotes effector T cells. 
At the same time vulnerability to apoptosis grows and effector T cell functions decrease (8). 
3.1.9 Characteristics of subpopulation of T memory cells  
A long persistence is an essential feature of immunologic memory T cells. In the periphery 
they survive a long time after antigen stimulation (and without presence of the antigen) and 
they are also able to proliferate. 
Memory cells differ from naive T cells along the following: 
i) responsiveness on small antigen concentrations 
ii) faster proliferation after antigen stimulation 
iii) faster exhibition of effector functions 
iv) ability to secrete a broad spectrum of cytokines 
v) expression of adhesion molecules in periphery tissues 
Memory T cells are less dependend on co-stimulation by antigen presenting cells. Secondary 
immune responses dominate naive primary responses so that memory T cells are excellent 
precursor cell for cytotoxic effector population (8). 
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3.2 Drug hypersensitivity 
Drug hypersensitivity reactions represent adverse effects of drugs, taken at a dose which is 
tolerated by normal subjects, which clinically resemble allergy. The classical pharmacological 
classification of adverse drug reactions (ADRs) divides these into two major subtypes: type A 
reactions, which are dose-dependend and predictable, and type B, which are neither. The 
majority of ADRs are type A reactions. Type B reactions constitute approximately 10-15% of 
all ADRs (14) and include all types of immunological hypersensitivity reactions (type I-IV): 
a) Type I hypersensitivity 
Type I is IgE mediated and is directed against soluble antigens, thus is called 
immediate type reaction (e.g. hey fever). Antigen specific IgE binds Fc-fragment of 
mastcells and basophils. The antigen binds to IgE and mastcells and basophils secrete 
their granula (1, 2). 
b) Type II hypersensitivity 
IgM and IgG are produced and bind to cell-associated antigen. Some antibiotic drugs 
(cephalosporin, streptomycin, penicillin) bind to surface proteins of erythrocytes and 
change the chemical structure of the proteins and their conformation. Erythrocytes are 
metabolized in the spleen (by APC) therefore new T cell epitopes are generated. 
Antigen specific naive CD4+ T cells can be directed against these epitopes and can be 
activated. Consequently specific B cells are activated against these surface proteins. 
Antigen specific antibodies are bound and complement system is activated at the 
second contact. Splitting products of complement (C5a) activate macrophages, so that 
erythrocytes can be phagocyted as in the case of erythroblastis fetalis (1, 2). 
c) Type III hypersensitivity 
Accumulation of immune comlexes in tissues or vessels causes Type III reactions. 
These consist of IgM and IgG and bind soluble antigens. Immune complexes are 
generated whenever infection occurs and are eliminated in the liver and spleen. When 
these complexes become overproduced, they sediment in the vessels and bind 
complement and Fc fragments via Fc fragments which results in an inflammation as in 
the case of viral hepatitis (1, 2). 
d) Type IV hypersensitivity 
Type IV is a delayed type reaction (24-72 h) due to the fact that primarily TH1 cells, 
CTLs have to be activated. TH1 cells activate macrophages that secrete cytokines and 
chemokines. More and more macrophages are attracted as in the case of contact 
allergy (1, 2). 
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3.3 Detection and characterization of drug hypersensitivity 
The lymphocyte transformation test (LTT) is an in vitro test that detects proliferation of T 
cells as a consequence of antigen presentation and cognition. The LTT is based on the 
principle of standard proliferation assays: the radioactive marked DNA-component thymidine 
(3H-thymidine) is integrated in proliferating cells. Detection of drug-specific stimulated T 
cells is an in vitro marker for drug sensitization in sensitized patients. It has to be noted that 
by means of LTT different clinical manifestations of drug-specific sensitization can be 
detected as in the case of hepatitis and cytopenia. 
The LTT is the only in vitro test for detecting drug sensitization at the cellular level 
irrespective of the reaction’s phenotype. However, the lymphocyte transformation test 
includes working with radioactive substances and is considered impracticable for routine 
laboratory investigation. 
 
In addition, sensitivity of the LTT is insufficient which is caused by different factors such as 
antigen (e.g. the culprit drug), clinical phenotype of the reaction, and others (15, 16). 
 
Drug hypersensitivity reactions account for only about one-seventh of all adverse drug 
reactions (15), but they represent a major problem in drug safety due to their severity and 
their unpredictability (17, 18). 
However, conclusive diagnosis of drug allergy still remains a major problem in daily clinical 
practice (19, 20). In vivo tests, such as patch, prick and intracutaneous tests often do not yield 
positive reactions, even in patients with well-documented histories of drug-allergic reactions 
(21, 22). Moreover, anaphylactic reactions associated with skin testing have been reported 
(23, 24). Challenge tests, which are considered to be the gold standard, are frequently not 
tolerated by the patients, bear the risk of severe reactions, and do not differentiate between 
allergic and pseudoallergic reactions (25, 26). 
As with in vivo tests, the usefulness of in vitro tests is also limited. Certain methods in use, 
e.g. the basophil activation test (BAT) are linked to the effector phase of the reaction. Hence, 
many drug-allergic reactions like the common maculopapular exanthema (MPE), which 
usually do not involve formation of drug-specific IgE, cannot be detected by means of these 
diagnostic methods (15). 
Currently, the LTT is the only available in vitro tool for detecting drug sensitization at the 
cellular level, irrespective of the effector mechanism and the clinical phenotype of the 
reaction (15). 
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However, the LTT imposes limitations in terms of practicability and sensitivity (15). In this 
respect, others and we have demonstrated that the in vitro detection of drug-specific cytokine 
production by peripheral blood mononuclear cells (PBMC) appears to be an adequate 
alternative for detecting drug hypersensitivities (17, 18). 
In the present study, this approach was further explored by focussing on flow cytometry as a 
test system and by including a panel of different cytokines. Cytokine secretion using ELISA-
techniques as described elsewhere, was assessed in parallel for validation. 
 
The aim of this pilot study was to assess drug-specific cytokine production by means of flow 
cytometry and ELISA as an alternative non-radioactive approach which may be more 
appropriate for routine testing and may provide more information about the pathophysiology 
of the reaction than proliferation-based assays (27). 
3.4 Hypersensitivity reactions to contaminated heparins 
Heparins currently represent one of the oldest pharmacological substances still in widespread 
use (28). The common chemical structure of all heparins is characterized by sulphate 
proteoglycan chains of different molecular weights (29). 
Due to their being composed of polyvalent anions, heparins have a high capacity for binding 
proteins and, theoretically, for forming conjugates which can induce specific immune 
responses (30). In fact, heparins are known to cause all types of allergic reactions (type I-IV) 
(31), though the exact underlying pathomechanisms are still unknown. 
Beginning in 2007, an increased occurrence of severe and in some cases fatal hypersensitivity 
reactions associated with unfractionated heparin (UFH) was reported (29, 32). These reactions 
were imputed to both the generation of bradykinin and the activation of the complement 
system associated with the administration of certain batches of UFH containing the adulterant 
oversulphated chondroitin sulphate (OSCS). 
Subsequently, the existence of two distinct heparin-induced hypersensitivities of either 
immune-mediated anaphylaxis induced by OSCS or non-immune-mediated anaphylactoid 
reactions was postulated. However, although the pathomechanisms of these two syndromes 
were discussed (33, 34), possible immune-mediated mechanisms were not further investigated 
(35). 
Hence, it was one aim of the present study to analyse the in vitro cytokine reactivity of PBMC 
of individuals with hypersensitivity reactions to contaminated heparin in comparison with 
PBMC of individuals with or without hypersensitivity to non-contaminated heparins or other 
drugs. 
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Drug-specific secretion of selected cytokines from PBMC of patients with hypersensitivity 
reactions to contaminated heparin were compared with the respective in vitro cytokine pattern 
of individuals with or without hypersensitivity to heparin, different glycosaminoglycans 
(GAG) or other drugs (36). 
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4 Materials and Methods 
4.1 Detection and characterization of drug hypersensitivity 
4.1.1 Method 
Peripheral blood mononuclear cells of 19 patients were incubated with culprit drugs (n=28) or 
irrelevant antigens (n=10). Ten healthy persons served as controls for all different drugs 
(n=15). 
Intracellular IL-5, IFN-g and IL-10 production was investigated by flow cytometry. Accuracy 
of the flow cytometry test system was confirmed using different statistical tests i.e. receiver 
operating characteristic (ROC) curve and Mann-Whitney rank test. 
In addition, drug-specific secretion of IL-5, IL-2 and IFN-g were analyzed by ELISA. 
4.1.2 Patients` characteristics 
Nineteen patients (average age: 53 years, range 29-84 years) with a history suggestive of drug 
hypersensitivity were included in this investigation serving for 38 antigen testings (n=28 
culprit drugs, n=10 irrelevant antigens) (Table 1). In all individuals, drug allergy was 
confirmed by stringent drug allergy history category A according to Nyfeler et al. (15). 
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Table 1. Clinical phenotypes of the 19 patients investigated 
 
A suspected atopy was not defined as a criterion for exclusion. The following classification is 
based on analysis of our own questionnaires and patients` files:  
i) atopy excluded (7/19);  
ii) atopy confirmed (4/19);  
iii) atopy neither excluded nor confirmed (8/19). 
Two control groups containing non-atopic individuals were included. In the first control 
group (n=6), a healthy control person, if possible age- and sex-matched without allergy to the 
tested drug and without intake of the drug in the last twelve months was matched to a 
respective patient. PBMC of these control persons were studied to rule out unspecific 
stimulating effects of the tested drugs. In the second control group, PBMC of four individuals 
were investigated who were currently or in the last three months exposed to the respective 
drug under investigation without clinical signs of a drug-allergic reaction. 
Altogether, these control persons (n=10) were tested with 15 different antigens used in this 
study. It was ensured that every substance tested in a patient was also tested at least once in a 
Reaction Patient Sex/ 
Age 
Time 
span 
Drug 
of main interest 
Additional drug 
of interest1 
Irrelevant 
antigen 
Bullous 
reactions 
n = 3 
TEN2 01 f/52 8 wk Lamotrigine   
SJS3 02 f/54 8 wk Amoxicilline Ampicilline Penicillin G  
SJS3 03 m/60 4 wk Proguanil   
Urticaria 
n = 2 
04 f/44 4 wk Doxycycline  Penicillin G 
05 f/44 8 wk Amoxicilline  Cotrimoxazole 
Angioedema 
n = 4 
06 f/58 20 y Penicillin G   
07 m/84 2 wk Ampicilline Cotrimoxazole Doxycycline  
08 m/52 8 wk Omeprazole Ibuprofen  
09 f/59 2 y Penicillin G  
Metamizole 
Metronidazole 
Cefuroxime 
Maculopapular 
exanthema 
n = 3 
10 f/58 4 wk Amoxicilline Penicillin G  
11 f/62 4 wk Clindamycine  Penicillin G 
12 m/41 12 wk Amoxicilline   
Exanthema4 
n = 4 
13 f/41 20 wk Carbamazepine  Valproic acid 
14 f/40 12 wk Clarithromycine Amoxicilline Pantoprazole 
15 f/29 4 wk Clindamycine  Penicillin G 
16 f/67 5 y Na-Perchlorate Iodixanol  
Misc.5 
n = 3 
Dyspnoe 17 f/44 8 wk Doxycycline  Cotrimoxazole 
Nausea 18 f/52 5 y Nadroparine   
Unknown 19 f/60 20 y Penicilllin G Omeprazole  
1 History of drug hypersensitivity to the substance, although not further evaluated, 2 TEN: toxic epidermal necrolysis,  
3 SJS: Stevens-Johnson syndrome, 4 Exanthema not further specified, 5 Misc.: Miscellaneous 
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control person although the total number of testings in patients exceeded those in controls due 
to severalfold testings. 
The present study was approved by the ethics committee of the Medical faculty of the RWTH 
Aachen (EK 100/06) and all patients gave written informed consent prior to participation. 
4.1.3 Drugs and antigens 
Drugs were used at nontoxic concentrations as described elsewhere (37). Directly before use, 
all drugs were dissolved in phosphate buffered saline (Dulbecco´s PBS, PAA) and diluted in 
up to three different concentrations which were analyzed in the ELISA. The medial 
concentration was analyzed in the flow cytometry system, which had been proved to be 
optimal for the stimulation and detection of PBMC in our own preceding experiments. All 
drugs except for the penicillins (1.0, 0.5, 0.1 mg/ml) and omeprazole (50, 10, 1 mg/ml) were 
included in concentrations of 100, 10, 1 mg/ml.  
The following antigens were obtained as pure substances:  
- Phytohemagglutinin PHA (Sigma-Aldrich, St. Lois, MO, USA) 
- Amoxicillin (Sigma-Aldrich, St. Lois, MO, USA) 
- Carbamazepine (Sigma-Aldrich, St. Lois, MO, USA) 
- Ibuprofen (Sigma-Aldrich, St. Lois, MO, USA) 
- Penicillin G (Sigma-Aldrich, St. Lois, MO, USA) 
- Valproic acid (Sigma-Aldrich, St. Lois, MO, USA) 
Solutions for infusion were used for:  
- Ampicilline (Ratiopharm, Ulm, Germany)  
- Clindamycine (Ratiopharm, Ulm, Germany) 
- Cotrimoxazole (Ratiopharm, Ulm, Germany) 
- Doxycycline (Ratiopharm, Ulm, Germany) 
- Metamizole (Ratiopharm, Ulm, Germany) 
- Cefuroxime (Fresenius, Bad Homburg, Germany) 
- Clarithromycine (Abbott Laboratories, IL, USA) 
- Nadroparine-Ca (Glaxo Smith Kline, London, UK) 
- Metronidazole (Infectopharm, Heppenheim, Germany) 
- Omeprazole (Astra Zeneca, Wedel, Germany) 
- Pantoprazole (Nycomed, Konstanz, Germany)  
- Tetanus toxoid (Sanofi Pasteur MSD, Paris, France) 
Materials and Methods  18 
Additional solutions were used for:  
- Na-perchlorate (Bayer Vital, Leverkusen, Germany)   
- Iodixanol (GE Healthcare Buchler, Braunschweig).  
Solutions were prepared based on crushed tablets for: 
- Lamotrigine (1A Pharma, Oberhachingen, Germany)  
- Proguanil (Astra Zeneca, Wedel, Germany)  
4.1.4 Cell preparation and culture 
The LTT served as a methodological platform in the experiments and hence, the first steps 
were performed in accordance with the LTT protocol as described elsewhere (15). Briefly, 
PBMC from patients and controls were isolated from heparinized whole blood by gradient 
centrifugation over Ficoll-Hypaque solution (Sigma-Aldrich, St. Lois, MO, USA) and 
cultured for up to 6 days in 96-well round-bottom plates as tenfold culture in RPMI 1640 
supplemented with 5% autologous heat inactivated plasma, sodium pyruvat (1 mM) and L-
glutamine (2 mM) at a concentration of 1x106 cells/ml under humidified conditions and 5% 
CO2 (all reagents PAA Laboratories GmbH, Pasching, Austria). 
At the beginning of the incubation (= day 0) the indicated drugs dissolved in PBS or with PBS 
alone (control) were added to the PBMC cultures in different concentrations. Incubations of 
the PBMC with PHA and tetanus toxoid served as positive controls for mitogen-induced and 
memory T cell antigen-specific lymphocyte reactivity, respectively. 
From the ten wells assigned to each drug concentration, four wells were dedicated to flow 
cytometry and six wells for the determination of IL-2, IL-5 and IFN-g in the supernatants by 
means of ELISA (two wells for each cytokine). Cell culture supernatants for analysis in the 
ELISA were taken at different time points from separate wells reflecting optimal conditions 
for the individual cytokine (see section results). 
4.1.5 Flow cytometry test system 
In contrast to the ELISA, only the wells incubated with the middle drug concentration were 
selected for flow cytometry analysis. Cells were harvested after 5 days of incubation, for the 
last 16 hours in the presence of brefeldin A (6 mg/ml), and then stained with anti-CD3 PerCP-
Cy5.5, anti-CD4 FITC, anti-CD8 APC (BD biosciences) for T cell phenotyping. Fixed and 
permeabilized cells (Cytofix/Cytoperm Plus Kit with BD GolgiPlug containing brefeldin A) 
were subsequently stained with PE-labeled anti-IFN-g, anti-IL-5 and anti-IL-10 specific 
monoclonal antibodies (BD biosciences) for intracellular cytokine detection. Stained cells 
were analyzed in a FACSCalibur (BD biosciences, Milpitas, CA, USA) and data were 
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processed with CellQuest software (BD Biosciences). 10,000 CD3+ cells were assessed in 
each sample. The recommended PE-conjugated IgG1k and IgG2ak were used (BD 
Biosciences) as isotype controls. 
4.1.6 ELISA test system 
The sandwich enzyme-linked immunosorbent assays (ELISA) for human IL-5 (range 7.8 – 
500 pg/ml), IL-2 (range 7.8 – 500 pg/ml) and IFN-g (range 4.7 – 300 pg/ml) were obtained 
from BD biosciences. The minimum detectable dose was defined by us as two standard 
deviations above the mean OD of 20 replicates of the zero standards. In preliminary testings 
minimum detectable doses between 0.5 and 1.5 pg/ml were obtained. 
According to similar instruction manuals for pre-coated plates, we defined a mean value of 
1.0 pg/ml for all cytokines (IL-2, IL-5 and IFN-g) as the cut-off. A Dynex MRX micro plate 
reader was used for the assays. The results of the highest value (based on three drug 
concentrations) are expressed as cytokine concentration (pg/ml). 
4.1.7 Statistical analysis 
The Mann-Whitney rank test, boxplots and ROC Curve were employed using SPSS software 
version 17.0 (SPSS Inc., Chicago, IL, USA). 
4.2 Hypersensitivity reactions to contaminated heparins 
Study individuals (n=13) were classified as follows: Patients with hypersensitivity reactions 
to contaminated (OSCS) heparin (n=3), non-contaminated heparin (n=1), other compounds 
(n=4) and patients with ongoing heparin therapy without symptoms of intolerance (n=2). 
Three healthy individuals served as controls. PBMC were incubated with six different 
glycosaminoglycan structures. 
Drug-specific intracellular IL-5, IFN-g and IL-10 production was investigated by flow 
cytometry, whereas secretion of IL-5, IL-2 and IFN-g was analyzed by ELISA. 
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4.2.1 Patients` characteristics 
Five groups of patients and controls with different clinical characteristics were included 
(Table 2). The classification is based on extensive information about the patients` medical 
history (patient interviews, patient files, evaluation of questionnaires). 
i) Individuals with severe adverse hypersensitivity reactions after treatment with 
OSCS-contaminated heparin (n=3), 
ii) healthy individuals (controls) with (n=1) and without (n=3) prior history of 
heparin intake, 
iii) individuals with assumed heparin hypersensitivity (n=1), 
iv) individuals currently receiving heparin therapy (n=2) without clinical signs of 
hypersensitivity, 
v) individuals with proven hypersensitivity to other compounds, but no heparin-
hypersensitivity (n=3). 
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Patient Sex/Age Interval1 Assumed Reaction
culprit substance
1 f/83 5 mo OSCS2 blood pressure drop, nausea
2 m/87 5 mo OSCS blood pressure drop, dyspnoe
3 f/82 5 mo OSCS blood pressure drop, nausea
4 m/79 5 mo OSCS blood pressure drop, dyspnoe
5 f/29 n.a.3 n.a. n.a.
6 f/30 n.a. n.a. n.a.
7 f/32 n.a. n.a. n.a.
8 m/19 n.a. n.a. n.a.
Individuals with assumed 9 f/53 10 y Nadroparine blood pressure drop, nausea
heparin hypersensitivity 10 f/33 5 y Certoparine blood pressure drop, nausea
Individuals currently 11 m/83 n.a. Certoparine n.a.
receiving heparin therapy
without cl inical signs 12 f/71 n.a. Certoparine n.a.
of hypersensitivity
13 f/25 12 mo Cotrimoxazole angioedema
14 f/55 6 mo Ofloxacine angioedema
15 m/28 10 y Amoxicil l ine urticaria
1 Time interval  between the reaction and start of thi s  s tudy
2 OSCS-contaminated heparin
iii)
Study group
i)
ii)
Individuals with 
hypersensitivity reactions 
after treatment with OSCS-
contaminated heparin
3 not appl i cable
Individuals with proven 
hypersensitivity to other 
compounds, but no 
heparin-hypersensitivity
Healthy individuals 
(controls) with (n=1) and 
without (n=3) prior 
history of heparin intake 
iv)
v)
 
Table 2. Study groups and clinical characteristics of individuals 
 
In our own pilot study (27), the mode of drug intake and the time span between intake and 
onset of the reaction are mentioned, but not further evaluated. 
The present study was approved by the ethics committee of the Medical Faculty of the RWTH 
Aachen (EK 100/06) and all patients gave informed consent in written form prior to 
participation. 
4.2.2 Antigens 
Directly before use, all antigens (Table 3, chemical structures) were dissolved in phosphate 
buffered saline (Dulbecco's PBS, PAA) and diluted in up to three different non-toxic 
concentrations (0.001, 0.0001, 0.00001mg/ml), which had been analyzed by ELISA. The 
selection of the applied drug concentrations is based on their non-cytotoxicity in healthy 
controls and on their non-inhibitory effect on the heparin-stimulated lymphocytes of a patient 
with heparin hypersensitivity, which was established in our preceding experiments (data not 
shown). As an addition to the ELISA testing, only one concentration was analyzed in the flow 
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cytometry system, namely the middle one of the three mentioned above, as this had been 
proved to be the one suited best for the in vitro detection of lymphocyte reactivity in 
preceding experiments by our group (27). 
 
Substance Molecular
weight
Degree of 
sulphation
Main components 
of disaccharide 
unit[kDa] Sulphate position
Unfractionated 
heparin,
5-30,000 0.9-1.25
R 1, R 3 
Low molecular 
weight heparin
17-50,000 0.4
R 2
18,000 4.0
R 1-R 4
15-40,000 0.7
R 2,  R 3
Dextran sulphate 15-500,000 2.3
R 1,R 5
Oversulphated 
chondroitin 
sulphate
Chondroitin 
sulphate A
Chondroitin 
sulphate B
O
CH2R1
NR2
OO
O
OR3
O
OH
COO-
OH
n
 
O
O
OR3
OR4
COO-
O
CH2R1
NHAc
O
O
OR2
n
 
O
O
OR3
OR4
O
CH2R1
NHAc
O
O
OR2
COO-
n
 
O
O
OR5 O
CH2OH
OR4
n
 
O
CH2
OR3
OR2
OR1
O
 
Table 3. Chemical structures of tested glycosaminoglycans 
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The following antigens were obtained as pure substances: 
- Heparin sodium contaminated with oversulphated chondroitin (Yantai Dongcheng 
Biochemicals Yantai Dev. Zone, Shandong, China), clindamycine (Ratiopharm, Ulm, 
Germany) 
- Heparin sodium containing chondroitin sulphate B (Lichtenstein, Hamburg, Germany) 
- Heparin sodium (Lichtenstein, Hamburg, Germany) 
- Chondroitin sulphate A CS-A (Sigma-Aldrich, St. Louis, MO, USA) 
- Dextran sulphate (Sigma-Aldrich, St. Louis, MO, USA) 
- Amoxicilline (Sigma-Aldrich, St. Louis, MO, USA) 
- Ofloxacine (Sigma-Aldrich, St. Louis, MO, USA) 
 
Solutions for infusion were used for: 
- Certoparin sodium (Novartis Pharma Distributions GmbH, Nürnberg, Germany) 
- Nadroparin calcium (Glaxo Smith Kline, London, UK),  
- Cotrimoxazole (Ratiopharm, Ulm, Germany).  
 
The solution used for parenteral administration was: Tetanus toxoid (Sanofi Pasteur MSD, 
Paris, France). 
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4.2.3 Cell preparation and culture 
The LTT served as a methodological platform which has been confirmed to detect drug-
specific T cells which are involved in almost every type of drug hypersensitivity (type I-IV) 
(27, 37, 38). According to an LTT standard procedure (37) and in the context of specifically 
investigating the effect of heparins (39, 40), whole blood cells from patients and controls were 
obtained using Li-heparin tubes (Sarstedt, Nümbrecht, Germany). In our preceding 
experiments with the antigen heparin no increased lymphocyte response - neither in the 
PBMC used for negative controls of sensitized patients nor in the PBMC of control persons - 
was observed. However, a delay of PBMC separation resulted in in vitro artefacts; hence 
separation had to be performed within six hours including a severalfold wash-out step to 
eliminate the anticoagulant. A marginal quantity of Li-heparin still remained in every sample 
tested, due to the application of 5% autologous heat-inactivated plasma. EDTA was not 
chosen due to its complexing characteristics (41). 
Subsequently, the PBMC were isolated by gradient centrifugation over Ficoll-Hypaque 
solution (Sigma-Aldrich, St. Louis, MO, USA) and cultured for up to 6 days in RPMI 1640 
which was supplemented with sodium pyruvate (1 mM) and L-glutamine (2 mM) at a 
concentration of 1x106 cells/ml under humidified conditions and 5% CO2 (all reagents PAA 
Laboratories GmbH, Pasching, Austria). 
At the beginning of the incubation, the indicated antigens, which had been dissolved in PBS 
were added to the PBMC cultures in different concentrations. Incubations of the PBMC with 
tetanus toxoid served as positive control, PBS alone served as negative control. 
4.2.4 Flow cytometry test system 
Cells were harvested after 5 days of incubation, for the last 16 hours in the presence of 
brefeldin A (6 mg/ml), and then stained with anti-CD3 PerCP-Cy5.5, anti-CD4 FITC, anti-
CD8 APC (BD Biosciences, Milpitas, CA, USA) for T-cell phenotyping. Fixed and 
permeabilized cells (Cytofix/Cytoperm Plus Kit with BD GolgiPlug containing brefeldin A, 
BD Biosciences) were subsequently stained with PE-labelled anti-IFN-g, anti-IL-5 and anti-
IL-10 specific monoclonal antibodies (BD Biosciences) for intracellular cytokine detection. 
Stained cells were analyzed in a FACSCalibur (BD Biosciences) and data were processed 
with CellQuest software (BD Biosciences). 10,000 CD3+ cells were assessed in each sample. 
The recommended PE-conjugated IgG1k and IgG2ak were used (BD Biosciences) as isotype 
controls. 
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4.2.5 ELISA test system 
The sandwich enzyme-linked immunosorbent assays (ELISA) for human IL-5 (range 7.8 – 
500 pg/ml), IL-2 (range 7.8 – 500 pg/ml) and IFN-g (range 4.7 – 300 pg/ml) were obtained 
from BD Biosciences. The minimum detectable dose was defined by us as two standard 
deviations above the average, here the mean optical density of 20 replicates of the zero 
standards (1 pg/ml). A Dynex MRX micro plate reader was used for the assays (Dynex 
Technologies, Berlin, Germany). The results of the highest value (based on three drug 
concentrations) are expressed as cytokine concentration (pg/ml). 
4.2.6 Basophil activation test 
The implemented basophil activation test (Flow-Cast®, Bühlmann Laboratories, Switzerland) 
was based on the in vitro detection of activated basophils revealing upregulation of CD63 
surface expression upon stimulation with the respective test compound. Adhering to the 
product manual, the leukocyte fraction of a 6 ml EDTA whole blood sample of each patient 
was isolated by centrifugation and carefully resuspended in 300 µl of an IL-3-containing 
stimulation buffer. The probes were incubated with the respective test compound  
(concentrations: 0.0001, 0.001, 0.01, 0.1, 1mg/ml), the stimulation buffer (negative control) or 
a monoclonal anti-FcεRI antibody (positive control). Subsequently, stimulation was 
terminated by incubation on ice and basophils were stained with an antibody reagent 
containing a monoclonal phycoerythrine (PE)-labelled anti-CD63 antibody and a monoclonal 
fluorisothiocyanate (FITC)-labelled anti-IgE-antibody. Finally, after lysis of erythrocytes, 
probe fixation and centrifugation, the percentage of CD63-positive (activated) basophils of 
the total number of all basophils was determined using flow cytometry (FACScan® flow 
cytometer, Beckton Dickinson Immunocytometry System, San José, USA). These results 
were performed by the Department of Dermatology and Allergology of the RWTH Aachen 
University Hospital. 
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5 Results 
5.1 Detection and characterization of drug hypersensitivity 
Drug-specific cytokine production could be demonstrated in 75% of the patients using flow 
cytometry and in 79% using ELISA, respectively. Combining ELISA and flow cytometry 
increased the sensitivity to 100%. Analysis of involved T cell subsets (e.g. CD4+ or CD8+; 
TH1 or TH2) allowed characterization of the in vitro lymphocyte reactivity pattern. 
5.1.1 Preceding experiments 
Preceding experiments were carried out in order to determine the conditions (including time 
courses) for the analysis of in vitro drug-specific activated PBMC in primary cultures in the 
following two systems, i) flow cytometry (detection of intracellular cytokines) and 
ii) ELISA (secreted cytokines). Concerning the flow cytometry test system, a maximum yield 
of drug-specific IL-5, IFN-g and IL-10 producing T cells was obtained after 5 days of 
incubation with the causative drug and with tetanus toxoid. In the ELISA maximal 
concentrations of IL-5 and IFN-g were detected after 6 days of incubation and maximal 
secretion of IL-2 was observed after 4 days of incubation (data not shown). 
5.1.2 Establishing flow cytometry as an in vitro tool 
Table 4 provides an overview of the results obtained in the flow cytometry test system 
following stimulation of PBMC from 19 patients with drug hypersensitivity. 
In this system, intracellular detection of selected cytokines in T cells and their subsets was 
used as read-out parameter in contrast to the detection of T cell proliferation in the 
conventional LTT (Figure 4). 
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Figure 4. Detection of intracellular cytokine production for selected cytokines 
In this example, upon exposure of the PBMC from a patient with carbamazepine-induced 
hypersensitivity to the drug of interest carbamazepine, a substantial increase of the 
percentage of T cells positive for the respective cytokine was noted. Due to the fact, that a 
total of 10,000 cells were analyzed, the percentage of detected cells could be multiplied by the 
factor 100 resulting in the absolute number of cells of interest. Accordingly, data were 
expressed as delta values (difference of cytokine positive T cells with and without 
stimulation). 
 
Employing a ROC Curve, the accuracy of this assay was analyzed. The coordinates of the 
curve provided guidance to determine what delta values (difference of cytokine positive T 
cells in the cultures with antigen and without antigen) should serve as the cut-off to 
distinguish positive from negative results (Figure 5). Based on the analysis of 54 results 
considered positive and 300 negative results (results considered negative n=174 plus controls 
n=126), a cut-off for the delta value of 100 cells was applied. 
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Figure 5. ROC curve of delta values obtained in the flow cytometry system for differentiating 
between positive and negative results 
The sensitivity and specificity relationship is plotted. The optimum cut-off point for 
identification of positive results at a delta value of 100 cells provided a sensitivity of 100% 
and a specificity of 97%. The area under the curve was 0.986 ± 0.006. 
 
5.1.3 Determination of cytokine secretion by means of ELISA 
In parallel to the analysis of intracellular cytokine production by flow cytometry, secretion of 
cytokines by the stimulated T cells was analyzed by means of ELISA. 
In Table 4 the highest absolute cytokine concentration obtained at three different concen-
trations is listed. 
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Culprit drug Pat.1 
T cell subset 
detected by flow cytometry 
Secreted cytokine 
detected by ELISA 
(pg/ml) 
IL-5 IFN-g IL-10  
CD4 CD8 CD4 CD8 CD4 CD8 IL-2 IL-5 IFN-g 
Amoxicilline 
n = 5 
05 - + - + - - 5  -    -   
10 - - - - - -  -   5  -   
12 - - - - - - 2  -    -   
14 - + + + + + - - - 
02 - + - - - - 13 21  -   
Ampicilline 
n = 2 
02 - + - + - - - -  -   
07 - + - - - + - - - 
Clarithromycine 14 - - - + - + 14 13 3 
Clindamycine 
n = 2 
11 + + - - - - - - - 
15 - + - - - -  -   10  -   
Cotrimoxazole 07 - - - + - -  -   7 5 
Doxycycline  
n = 3 
04 - - - - - -  -    -   3 
07 - - - + - - - - - 
17 - - - - - - 6  -   31 
Penicillin G 
n = 5 
02 - - - + - - - - - 
06 + + - - - + 4  -   17 
09 - - - - - - 21 15 75 
10 - - - - - +  -    -   14 
19 - - - - - +  -    -   3 
Proguanil 03 + + + + + +  -    -   3 
Carbamazepine 13 + + + + + - 63 72 11 
Ibuprofen 08 - - - - - - 2 3 2 
Iodixanol 16 - + - + - +  -   2 3 
Lamotrigine 01 + + + + + + 34 6 109 
Nadroparine 18 + - + - + +  -   9 14 
Na-perchlorate 16 - + - + - - 5  -    -   
Omeprazole 
n = 2 
08 - - - - - - 2 4 2 
19 - - - - - +  -    -   5 
Sensitivity 
50% 46% 43% 43% 43% 57% 
75% 79% 
100% 
1 Patient number (Table 1) 
Table 4. Flow cytometry and ELISA results of 28 culprit drugs 
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Based on the analysis of 64 results considered positive and 509 results considered negative, a 
cut-off for an OD-difference between unstimulated and stimulated sample of 0.035 was 
applied. Statistics were performed with the OD and not the cytokine concentration, due to the 
fact that the OD is the parameter that is primarily detected. 
To give an estimate for comparison, an OD difference of 0.035 corresponded with 
concentration differences of about 2-3 pg/ml depending on individual test conditions (e.g. 
calibration line). 
5.1.4 Statistical analysis of investigated parameters 
In Figure 6, the obtained data for reactions considered positive or negative and controls are 
depicted by means of boxplots containing the respective five-number summaries: the smallest 
observation, lower quartile, median, upper quartile and largest observation. The differences 
between the positive results and the corresponding controls were tested using the Mann-
Whitney test and p-values were calculated for each parameter and method. Concerning flow 
cytometry, statistical significant differences between positive delta values from drug-allergic 
patients in comparison to delta values from controls were observed for all parameters. The 
corresponding statistical p-values for significance ranged between 0.000 and 0.008. With 
regard to the ELISA findings, Mann-Whitney testing revealed statistical significant 
differences between SIs considered as positive or negative, and controls, respectively for all 
cytokines investigated (p-values of 0.000 for IL-2, IL-5 and IFN-g, data not shown). 
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Figure 6. Comparison of different parameters 
The boxplots depict the delta values (D) of patients tested positive or negative and respective 
controls, through their five-number summaries: the smallest observation, lower quartile, 
median, upper quartile and largest observation. Statistically confirmed outliers (Ñ, •) are 
shown separately. Differences between the study groups were tested using the Mann-Whitney 
test and are described as p-value. 
 
5.1.5 Sensitivity 
Based on the testing of 28 drugs of interest, the sensitivities of both in vitro approaches were 
analyzed separately according to the different single parameters and the two different methods 
(Table 4). Single cytokine analysis led to sensitivities ranging from 43% up to 57%, whatever 
method used. By testing a panel of relevant cytokines a sensitivity of 75% in the flow 
cytometry and 79% in the ELISA was observed. Combining both methods increased 
sensitivity to 100%. 
5.1.6 Specificity 
No significant cytokine concentrations or productions were detected when PBMC of control 
persons were incubated with the various drugs investigated. Substantial production and 
secretion of cytokines were detectable following stimulation with tetanus toxoid or the 
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mitogen phytohemagglutinin, serving as positive control for PBMC of patients and controls. 
Furthermore, in sensitized patients no T cell-activation could be detected following 
stimulation with non-suspected tolerated co-medication or other irrelevant antigens  
(n= 10) (Table 1) resulting in a specificity of 100%. 
5.1.7 In vitro lymphocyte reactivity pattern 
Table 4 provides an overview of the results of all parameters. Flow cytometry offered 
information about the in vitro phenotype of the reactions and allowed to differentiate between 
the involvement of: i) CD4+ or CD8+ T cells; ii) TH1 (IFN-g) or TH2 (IL-5) T cells. 
The ELISA provided additional information about the cytokines secreted. 
No consistency between the involved T cell subset and either the clinical phenotypes or the 
class of drugs could be observed in both methods. 
 
Analysis of drug-specific cytokine production by means of flow cytometry proved a useful 
and reliable approach for the in vitro detection and characterization of drug hypersensitivities. 
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5.2 Hypersensitivity reactions to contaminated heparins 
 
PBMC from individuals with hypersensitivity reactions to contaminated heparin secreted 
considerable amounts of IL-2 in vitro. There was a suggestion that ongoing heparin therapy 
and the Li-heparin in the vials may have impact on the PBMC's lymphocyte reactivity. 
5.2.1 Overview of the findings 
The results obtained in this investigation were not in accordance with the concepts of an 
either strictly immune or a strictly non-immune-mediated reaction. Firstly, the expected 
responses of high levels of cytokine secretion were obtained for all but two patients following 
stimulation with tetanus toxoid (Figure 7A). 
Secondly, as expected, PBMC from patients with classical drug allergies secreted significant 
amounts of IL-5 and IFN-g after exposure to the relevant drug. 
For the patients with heparin-related hypersensitivity, PBMC stimulated with OSCS-
contaminated heparins secreted IL-2 (Figure 7B). In unstimulated cultures of PBMC from 
both from controls and patients, there was no detectable secretion of cytokines (Figure 7C). 
Results  34 
 
Figure 7. Comparison of selected cytokines as secreted by PBMC from the different study 
groups and detected by ELISA 
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A) Cytokine secretion of tetanus toxoid-stimulated PBMC (positive control for immune-
mediated reactions) from 11 patients in the current study compared to the respective results 
in our pilot study (n=patients and controls). Results from two patients were excluded (left 
part) due to assumed heparin-mediated inhibition (see section results). 
B) Cytokine secretion of PBMC stimulated with the respective suspected antigen from 6 
patients compared to the respective results in our pilot study (n=patients and controls). Here 
"n" refers to the number of antigen testings and not to the number of patients tested (which 
were 3 in the current study and 19 in the pilot study). In addition, only the positive results of 
all antigen testings are demonstrated since there is no difference with negative results. With 
regard to the patients with hypersensitivity to OSCS contaminated heparin, a marked IL-2 
secretion in the absence of any IL-5 or IFN-y secretion is noticed which stands in contrast to 
the pattern observed from PBMC of patients with drug hypersensitivity in our pilot study. 
C) Cytokine secretion of unstimulated PBMC (media control) from all 13 participants in the 
currentstudy are compared to the respective results in our pilot study (n=patients and 
controls). 
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5.2.2 Excluded data 
The PBMC of two patients had to be excluded because they could not successfully be isolated 
after mor than 6 hours of storage in Li-heparin treated tubes. One of those patients had 
(patient 10, Table 2) a suspected heparin allergy and the PBMC from another patient (patient 
4, Table 2) reacted to OSCS. This aspect is worth mentioning due to the fact that according to 
a standard protocol as well as to our experience (27, 37), a successful separation of PBMC 
can be performed within 24 hours. As a consequence, in this study, the PBMC of all patients 
with a history of heparin or OSCS sensitization were isolated within 2-6 hours. 
5.2.3 Patients with severe adverse reactions after treatment with 
OSCS-contaminated heparin 
Following incubation with contaminated heparin, intracellular cytokine production was 
detected in the flow cytometry in PBMC of all three patients (Table 5). It was, however, also 
seen following incubation with various GAG structures devoid of OSCS. Concerning the 
detection of secreted cytokines by means of ELISA, only in one of the three patients did 
incubation with the suspected antigen OSCS result in T-cell stimulation. However, the PBMC 
of the other two patients reacted, following exposure to GAG devoid of OSCS. As a common 
feature it can be noted that the PBMC of all three patients secreted high amounts of IL-2 but 
no IL-5 or IFN-g. In summary, no clear relationship could be established between the positive 
results and molecular weight or position/degree of sulfation by means of flow cytometry or 
ELISA. 
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Study BAT1
group IL-2 IL-5 IFN-g CD63 
CD4 CD8 CD4 CD8 CD4 CD8 (%)
Heparin +OSCS - + - - - - - - - 2.86
Heparin - + - - - - 33.9 - - 5.26
Heparin +CS-B + + - + - - - - - 3.89
CS-A - + - - - + 26.0 - - n.a.2
Dextran sulphate - + - - - - 73.8 - - n.a.
Heparin +OSCS - - + - - - 31.6 - - -
Heparin - - + + - - - - - 2.59
Heparin +CS-B - - - - - - - - - 3.83
CS-A - - - - - - - - - n.a.
Dextran sulphate - - - - - - - - - n.a.
Heparin +OSCS - + - + - - - - - 6.22
Heparin - - - - - - 36.8 - - 3.56
Heparin +CS-B - - - - - - - - - 5.06
CS-A - - - - - + - - - n.a.
Dextran sulphate - - - - - - 21.1 - - n.a.
(pg/ml)
Patient Substance Flow cytometry ELISA
IL-5 IFN-g IL-10
i ) Individua l s  with hypers ens itivi ty reactions  a fter treatment wi th OSCS-contaminated heparin
1 Bas ophi l  activation tes t; Backrounds timulation: Pat. 1 (0.67%), Pat. 2 (1.25%), Pat. 3 (1.92%)
i)
2 not appl icable
1
2
3
 
Table 5. Individuals with hypersensitivity reactions after treatment with OSCS-contaminated 
heparin 
 
As a third diagnostic approach, CD63 expression of the patients' basophils was investigated 
following incubation with the different antigens. Initially, to establish cut-off points for new 
allergens (here: GAG) it would have been desirable to set up ROC-analysis as it was done for 
the flow cytometry and ELISA test system in our own preceding experiments (27). 
Unfortunately, due to the small sample size, these calculations could not be performed in the 
present study. However, each stimulation with the antigens tested (except contaminated 
heparin in patient 2) resulted in a higher percentage of CD63+ cells than the following 
stimulation with the solvent (background). Even though positive reactions to various 
concentrations of antigens tested were seen, the percentage of CD63+ cells did not exceed 
6.2% (Table 5). This is considered a marginal finding which may be addressed as negative 
compared to other results published in literature (42). Again, there was no clear relationship 
between positive results and molecular weight or position/degree of sulfation. 
Results  38 
5.2.4 Control individuals 
No in vitro cytokine secretion (ELISA) or production (flow cytometry) could be observed 
with PBMC from healthy individuals with (n=1) or without (n=3) previous application of 
heparins (data not shown). 
5.2.5 Patients with heparin hypersensitivity 
Table 6 presents data of the one patient with hypersensitivity to nadroparine, who served as an 
example of the intracellular/extracellular cytokine pattern to be detected in cases of proven 
drug hypersensitivity. As in other patients with drug hypersensitivity tested in our pilot study 
(27), drug-specific cytokine production (flow cytometry) and secretion (ELISA) of IL-5 and 
IFN-g following incubation with nadroparine were noted. In addition, positive results were 
also obtained for dextran sulphate. 
Initially, the PBMC of two patients with heparin hypersensitivity were investigated. However, 
as described above, data of one patient had to be excluded due to unsuccessful PBMC 
separation. Unfortunately, due to the distance of the patient's place of residence, no second 
blood sample could be obtained. 
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Study
group IL-2 IL-5 IFN-g
CD4 CD8 CD4 CD8 CD4 CD8
Nadroparine + - - + + + - 9.3 13.7
Dextran sulphate + - - - - + - - -
Certoparine - - - - - - - - 7.9
Heparin +OSCS - - - - - - - - 7.3
Heparin +OSCS - - - - - - 6.6 - -
Dextran sulphate - - - - - - - - 9.0
Cotrimoxazole - - - + - - 40.3 45.4 216.8
Heparin +OSCS - - - + - - - - -
Heparin - - - + - + - - -
Heparin +CS-B - - - - - + 7.7 - 25.5
Dextran sulphate - - - - - - 3.4 - -
Ofloxacine - - - - - + - - -
Heparin +OSCS - - - - - + - - -
Heparin +CS-B - - - - - + - - -
Amoxicil l ine - - - + - + 9.5 - -
Heparin - - - - - - 9.3 - -
Dextran sulphate - + + + + + - - 8.9
i i i ) Individuals  with as sumed heparin hypersens i tivi ty
iv) Individua ls  currently receiving heparin therapy without cl inica l  s igns  of hypersens i tivi ty
v) Individua ls  with proven hypers ens i tivi ty to other compounds , but no heparin-hypers ens i tivi ty
1 Heparin intake observed
2 No heparin intake before
(pg/ml)
Patient Substance
iii) 9
Flow cytometry ELISA
IL-5 IFN-g IL-10
iv)
v)
13 1
14 1
15 2
11
12
 
Table 6. Individuals with heparin hypersensitivity (n=1; group iii), individuals currently 
receiving heparin therapy (n=2; group iv), and individuals with proven hypersensitivity to 
other compounds (n=3; group v) 
5.2.6 Patients with ongoing heparin therapy 
In consideration of the suggested anti-inflammatory properties of heparin (43), the PBMC of 
two patients (Table 6) without a history or signs of heparin hypersensitivity were tested to 
study the in vitro reaction under conditions of currently ongoing heparin therapy (at least 
seven days). Whereas in the flow cytometry analysis a strong positive reactivity following 
incubation of the patients' PBMC with tetanus toxoid was noted, constituting a positive 
control for immune-mediated reactions, the secretion of cytokines (ELISA) following 
stimulation with tetanus toxoid was almost completely inhibited (data not shown). 
Following stimulation of the PMBC of both patients exposed to contaminated heparin, a weak 
cytokine secretion was detected in the ELISA. In addition, the PBMC of patient 11 reacted 
positively to certoparin in the ELISA and the PBMC of patient 12 to dextran sulphate. 
Effects of heparin on lymphocyte reactivity could be detected in the PBMC from patients with 
ongoing heparin therapy. 
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5.2.7 Patients with proven drug allergy to other compounds 
PBMC from patients with a history of drug hypersensitivity to other substances than heparins 
showed positive in vitro results (production and secretion of cytokines) to different GAG-
structures (Table 6), whether they had previously received heparin or not. These results were 
intense in a patient who had a history of a severe cotrimoxazole-induced allergic reaction and 
multiple food allergies (patient 13). 
Interestingly, IFN-g which besides IL-5 is considered to be a specific in vitro marker of drug 
hypersensitivity, was secreted in very high amounts after stimulation with standard heparin. 
Though the latter was once tolerated once by the test person, a sensitization could not be 
excluded. 
Lymphocyte reactivity of all patients with a proven allergy to other compounds could be 
detected, although the molecular structures of suspected antigens differed from the GAG 
substances tested. 
 
The in vitro lymphocyte reactivity pattern of PBMC from individuals with hypersensitivity 
reactions to contaminated heparins was neither typical for an immune-mediated nor for a non-
immune-mediated reaction. Possible effects of heparins in the test system itself may require 
consideration. 
Discussion  41 
6 Discussion 
6.1 Detection and characterization of drug hypersensitivity 
In the present study we could demonstrate that determination of drug-induced IL-5, 
IFN-g, IL-10 production by means of flow cytometry proved a non-radioactive, alternative 
approach for the in vitro detection of drug-sensitization. To the best of our knowledge, the 
employment of flow cytometry in this specific context has not been described before (44, 45). 
As a pre-condition for our statistical model we hypothesized that in vitro lymphocyte 
reactivity should be demonstrable in PBMC of all 19 selected patients (category A according 
to Nyfeler (15)). In order to establish a test system that proves itself on “real-life conditions”, 
no restriction concerning culprit drugs or clinical phenotypes was done. 
The TH2-like cytokine IL-5 and the TH1-like IFN-g were selected as in vitro read-out 
parameters for both methods based on studies suggesting their inclusion in this context (17, 
46, 47). 
Likewise, secretion of the T cell growth factor IL-2 was analyzed in the ELISA system with 
reference to its inclusion in previous studies. In the flow cytometry test system we 
additionally investigated IL-10, because this TH2-like cytokine is assumed to skew TH1 into a 
TH2 immune response (48, 49). The usefulness of such a cytokine panel containing IL-5 and 
in addition IL-2 or IFN-g has also been described for extracellular cytokine detection (12). 
Interestingly, we found drug-specific cytokine detection to be time dependent in our 
experiments. Concerning flow cytometry, preceding investigations indicated that for all 
cytokines studied, analysis is best performed after 5 days of incubation, since no positive 
reactions were observed with a shorter incubation time. Conversely, the vulnerability of the 
PBMC, e.g. during the staining process, increased substantially beginning with the sixth day 
of incubation. 
In the ELISA maximal concentrations of IL-5 and IFN-g were observed on the sixth day of 
incubation as reported elsewhere (17, 45). IL-2 was detectable as early as at day two with a 
maximum yield obtained on the fourth day. Subsequently IL-2 concentrations decreased 
probably due to consumption by T cells. 
It is important to point out that in the flow cytometry system the delta values were calculated 
with absolute cell numbers, irrespective of the cell volume. In contrast, cell volume impacts 
on the normalized mean fluorescence intensity (NMFI), which is calculated by multiplying 
the percentage of cells considered positive with the mean fluorescence intensity of the cell 
population of interest (50). In this study the calculation of a NMFI was not useful, since the 
sensitivity of flow cytometry test system would have been decreased due to the impact of 
Discussion  42 
large cells in the stage of proliferation. However, the aim of this study was to create a test 
system which allows detecting cells that were stimulated, although neither proliferation nor 
cytokine secretion maybe observable. 
The sensitivity was calculated for all parameters investigated and both methods applied. 
As one result, analysis of a single cytokine only - even if assumed to be involved in the 
pathophysiology of the particular clinical phenotype - was not helpful to detect lymphocyte 
reactivity in all different clinical phenotypes of drug sensitization (see results). 
Based on a panel of cytokines investigated, we calculated a sensitivity of 75% for the flow 
cytometry and 79% for the ELISA, respectively. Although the ELISA test system seemed to 
be superior in relation to flow cytometry, it has to be noted that the statistics of the ELISA 
were based on the results of three different concentrations in contrast to flow cytometry 
(result based on a single concentration). Concerning the ELISA test system, other groups 
reported similar or even higher sensitivities for distinct clinical reactions. For instance, 
Halevy et al. calculated a sensitivity of 50% for urticaria and angioedema based on the IFN-g 
release of drug-specific activated PBMC (51). In a study with test conditions similar to ours, a 
high sensitivity for in vitro detection of IL-5 (92%), but not IFN-g (36%) and IL-10 (50%) 
was observed, however, including patients with MPE only (17). 
Concerning in vivo tests, Barbaud et al. (52) investigated patients with cutaneous adverse drug 
reaction and described a sensitivity of 50% and 65% for patch and intradermal tests, 
respectively. This compares to the sensitivity of single cytokine analysis in the present study, 
whatever method was used. However, if a panel of cytokines was investigated, sensitivity 
increased to 75% and 79% for flow cytometry and ELISA, respectively, suggesting at least 
non-inferiority compared to the in vivo tests. Since a broad spectrum of different antigens and 
clinical phenotypes was investigated, the cytokine panel included, seemed to be suitable for 
the detection of drug hypersensitivity. 
Concerning the TH1/TH2 dichotomy, Fernandez et al. (53) described that the expression of 
cytokines and cytokine receptors in both, skin biopsies and peripheral CD4+ T cells, are in 
accordance with a TH1 profile in patients with MPE. Our in vitro data concerning a 
preferential involvement of CD4+ and/or CD8 + T cells and the TH1/TH2 dichotomy appear 
inconsistent and in view of the clinical phenotype not following theoretical considerations or 
dogmas (Table 4). These inconsistencies, however, may be explained by differences in the 
individual test systems applied. In addition, quantitative differences of cytokines may not 
necessarily translate into qualitative differences since the biological activity of equal amounts 
may be different. Further on, it is unclear, if the intracellular cytokine detection pattern is 
representative for the overall (production/secretion) cytokine patter. 
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Overall this investigation suggests that the flow cytometry test system is a helpful non-
radioactive approach for the detection and characterization of drug hypersensitivities. It may 
provide a viable diagnostic alternative for instance in patients with a history of severe 
cutaneous drug reactions or life-threatening anaphylaxis in whom drug challenge testing is not 
recommendable. However, further studies comprising larger patient populations and a broader 
range of investigated substances are warranted to corroborate the findings of our study (27). 
6.2 Hypersensitivity reactions to contaminated heparins 
In this part of the study, in vitro cytokine patterns of patients with hypersensitivity reactions 
to contaminated heparin were compared with in vitro cytokine patterns of individuals with or 
without hypersensitivity to heparin, different glycosaminoglycans or other drugs. 
The test system applied, i.e. the in vitro detection of cytokines following exposure to the 
suspected antigens and controls, is based on the LTT. Its validation has been described 
elsewhere (37). 
The main finding was that PBMC from patients with hypersensitivity reactions to 
contaminated heparin secreted considerable amounts of IL-2 in vitro and that this cytokine 
pattern differed from the other groups investigated. However, no clear relationship was 
observed with regard to molecular weight or structure, position/degree of sulfation, or mode 
of action. 
 
Heparin is most probably a mixture of allergen components and it was suggested that there 
are several epitopes responsible for different forms of hypersensitivity reactions (31, 54). In 
connection with the incidents attributed to OSCS-contaminated heparins, the severe adverse 
reactions were considered to be generally associated with the high degree of sulphation (28). 
The resulting highly negative charges create a strong protein-binding capacity. In the 
literature, the term cross-reactivity was mentioned in connection with LMWH (55) and in 
previous studies, in which a patient with announced ArteparonÒ hypersensitivity (an OSCS-
compound that was used for the treatment of degenerative joint lesions) expressed in vitro 
reaction to heparins without any previous intake (56). In this context a pre-sensitization was 
discussed. However, it has to be noted that the exact epitope structures responsible for a 
sensitization had not been found yet. These considerations are in accordance with our results 
which could be explained by cross-reactivity of pre-sensitized T cells against highly sulphated 
GAG structures tested. In this study cross-reactivities were not clearly associated with 
molecular structures. 
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Furthermore, heparins may have an exceptional position among all of our tested antigens 
since they are known to have anti-inflammatory effects and self-immunosuppressive 
characteristics (40). In this respect, the results obtained in our study with regard to two 
patients who were currently treated with heparin indicate that heparin has effects on the 
immune system. Secretion of cytokines was almost completely inhibited after stimulation 
with the positive control (tetanus toxoid), but was detected after stimulation with GAG. 
Consequently, current heparin intake could be an interfering or even excluding criterion for 
investigations of lymphocyte reactivity in corresponding LTT-based test systems. 
 
The exact pathomechanism of OSCS-associated hypersensitivity reactions remains to be 
elucidated. Some groups suggested non-immune-, but kallikrein-mediated effects (Figure 8) 
(35). This, however, is in conflict with the results of our study since the activation of 
kallikrein should have also resulted in activation of PBMC from the control persons (35). In 
addition, complement (C3a and C5a induction) and kinines should have been destroyed in the 
process of heat inactivation of autologous plasma performed as a step in the isolation of the 
PBMC (see material and methods).  
An underlying unspecific immune reaction comparable with mitogen stimulation as an 
assumed pathomechanisms for OSCS-associated hypersensitivity appears unlikely given the 
in vitro non-reactivity of PBMC from the control persons. Besides, marginal positive results 
by means of basophil activation tests were obtained after stimulation with almost every 
substance (contaminated heparin, pure heparin, pharmaceutical heparin) (36). 
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Figure 8. Clinical manifestations associated with OSCS-contaminated heparins were linked 
to either anaphylactoid, anaphylactic or other mechanisms as discussed in the literature. In 
this study analysis focused on stimulated T cells which could initiate IgE-production of B 
cells. Effector cell involvement was assessed; however, no unequivocal involvement of either 
immune-mediated or non-immune-mediated mechanisms could be observed. 
 
In this study, heparin-specific secretion of IL-5 and IFN-g could not be observed (12, 17, 57), 
however, considerable secretion of the T-cell growth factor IL-2 was detected. Since most or 
all T cells produce IL-2 following antigen stimulation (58), secretion of IL-2 in PBMC from 
patients with OSCS-associated reactions is no proof for an antigen-specific T-cell activation 
but may – to some extent – also reflect unspecific mechanisms. With regard to the marginal 
basophil activation observed, IL-2 is not typically mast-cell derived (59), arguing against the 
mast cells as a source of the IL-2 secretion. 
It is emphasized finally, that although secretion of IL-5 and IFN-g was not detected, the 
production of these cytokines was demonstrated intracellularly by means of flow cytometry.  
However, such differences between secretion and production of cytokines, which impacted on 
the sensitivity of both methods, were noticed in our own preceding experiments (27). 
An alternative explanation of the pathomechanism of the OSCS-associated reactions may be 
overlapping effects of the effector cells in both specific and unspecific immune responses. 
Overlaps are due to mutual triggering effects of different mediators (60). Anaphylactoid and 
anaphylactic reactions have also been described in association with polyacrylonitrile 
membranes used in hemodialysis (60). Unlike patients with OSCS-associated reactions, upon 
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in vitro challenge of PBMC from a patient with heparin allergy, a "secondary immune 
response" of T memory cells was expected (15) and could be observed in a previous study 
(27). The specific immune response was represented by production and secretion of TH1- and 
TH2-like cytokines (IFN-g and IL-5). In addition, IL-10 production was detected. 
In conclusion, the strong in vivo reactions could have involved T cells, but the in vitro type of 
reaction appears to be different from other allergic responses in vitro. 
In this respect, the markedly elevated rate of IL-2 secretion detected in our investigation 
would also suggest an intolerance to further heparin applications, but all patients with 
reactions to contaminated heparin who were switched to non-contaminated heparin, tolerated 
this well. 
 
In summary, truly allergic, immune-mediated hypersensitivity to a heparin exhibited in vitro 
findings different from those of the suspected non-immune-mediated hypersensitivity to 
OSCS-contaminated heparins. Possible effects of heparins on the test system itself may 
require consideration (36). 
6.3 Cytokine determination as a read-out system for T-cell 
reactions to drug 
6.3.1 In vitro detection of T-cell reactions to drug 
Currently, the LTT is the only available in vitro tool for detecting drug sensitization at the 
cellular level, irrespective of the effector mechanism and the clinical phenotype of the 
reaction. However, a lack of sensitivity (60-70%) and specificity (ca. 85%) limit the test 
system (37). The results of the conventional test system offer no characterization of the 
pathophysiology of the reactions and furthermore, radioactive detection is laborious. 
6.3.2 Cytokines as a read-out system 
Although cytokines are known to regulate the innate and adaptive immune systems, a major 
progress has been made in understanding the role of cytokines in adverse drug reactions. They 
control the intensity and type of immune response and the role of cytokines in ADRs could be 
investigated by using animal models (61), genetics (62), in vivo- (63) and in vitro-testings 
(17). 
 
The discussion of cytokine involvement in ADRs is organized according to target organs; 
specifically, ADRs targeting skin and liver. This study focussed on skin ADRs due to the fact 
that the classification of the clinical phenotype was typed including the helpful evaluation of 
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skin eruptions. In addition, cytokine selection has been performed according to studies 
referring to skin ADRs (17). 
 
In Table 7 some characteristic features and the role of cytokines are summarized. However, it 
has to be pointed out that these informations are collected by several studies based on 
different laboratory methods and type of specimens used for analysis. 
 
Immediate skin reactions occuring within 24 h are mainly IgE-mediated. These reactions 
often include IL-4 and IL-13, which promote B cell proliferation, differentiation and isotpe 
class switching to IgE antibodies (64). 
 
Delayed skin ADR can occur anywhere from 48 h to several weeks after initiating drug 
therapy (65). The clinical manifestation of delayed skin reactions are highly variable, ranging 
from mild maculopapular reactions to severe life-threatening SJS and TEN. 
It has been found out that IL-5 is thought to be a major cytokine involved in maculopapular 
exanthema due to its ability to recruit eosinophils to the site of inflammation (66). 
 
With regard to fixed drug eruptions (FDE) it has been found out that IL-8 is likely important 
for recruiting neutrophils to the site of inflammation, while IFN-g could enhance T cell 
cytotoxicity by upregulating MHC II expression on keratinocytes (67).  
 
SJS/TEN are considered the same disease with different degrees of severity.  
Clinically, these reactions appear as widespread blistering on the skin accompanied by skin 
detachment (68). The blister fluid contains high levels of IFN-g and TNF-a (69). TNF-a 
likely contributes to skin lesions by inducing keratinocyte apoptosis (70). 
 
The term drug hypersensitivity syndrome refers to skin rash with systemic symptoms. This 
type of reaction usually appears 3-4 weeks after initiating drug therapy (68). In vitro 
approaches had failed to identify a predominant TH1 or TH2 cytokine profile (63). 
 
There is also evidence to suggest that cytokines might play a regulatory role in delayed skin 
reactions by limiting the extend of injury. Specifically, the presence of IL-10 in fixed drug 
eruption blisters is thought to limit the extend of injury associated with this type of skin ADR 
(6, 68). 
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IgE mediated
IL-4 B cell  proliferation
IL-13 Isotype class switching to IgE
necrotic keratinocytes
T cells, eosinophils
IL-5 Eosinphil  recruitment
IL-8 Neutrophil recruitment
IFN-g MHC II upregulating on keratinocytes
CD8+ T cells
IFN-g
TNF-a Keratinocyte apoptosis
IL-10 Limitation of injury
no predomminant
TH1 or TH2 pattern
Drug 
hypersensitivity 
syndrome
Delayed skin 
ADR
Clinical phenotype Characteristic features and role of cytokines
Immediate skin ADR
Maculopapular 
exanthem
Fixed drug eruption
SJS / TEN
 
Table 7. Characteristic features and role of cytokines 
6.3.3 In vitro detection of drug hypersensitivity 
6.3.3.1 Cytokine selection 
Investigation of TH1-like (IFN-g) and TH2-like (IL-5) cytokines allowed more insight into the 
pathomechanism of in vitro cytokine pattern. Especially, the cytokines IL-5 and IFN-g proved 
to be reliable parameters for the detection of drug hypersensitivities. However, these studies 
were focussed on selected clinical phenotypes such as MPE or selected drugs such as 
penicillin (17, 46, 47). 
 
In the pilot study done by the researcher, a new method of intracellular cytokine detection was 
investigated using flow cytometry to improve the sensitivity of the test system. It could be 
demonstrated that the determination of drug-induced IL-5, IFN-g, IL-10 production by means 
of flow cytometry proved to be a non-radioactive, alternative approach for the in vitro 
detection of drug-sensitization. 
In the pilot study the TH2-like cytokine IL-5 and the TH1-like IFN-g were selected as in vitro 
read-out parameters for both methods based on studies suggesting their inclusion in this 
context. 
Likewise, secretion of the T cell growth factor IL-2 was analyzed in the ELISA system with 
reference to its inclusion in previous studies. In the flow cytometry test system we 
additionally investigated IL-10, because this TH2-like cytokine is assumed to skew TH1 into a 
TH2 immune response (48, 49). The usefulness of such a cytokine panel containing IL-5 and 
likewise the addition of IL-2 or IFN-g has also been described for extracellular cytokine 
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detection. However, it has been shown that investigations of less specific cytokines were not 
helpful (12). 
 
The cytokine selection depends on the objective of the study. Focussing on a single cytokine 
such as IFN-g for instance permits detailed information about its occurrence in different 
clinical phenotypes. 
With further development of detection methods and reagents, investigation of a panel of 
cytokines became more and more practically. Due to the fact that cytokines never act alone, 
the investigation of assumed cytokine antagonists (TH1- and TH2-like) or cytokines that are 
supposed to play a role in different clinical phenotypes (IFN-g, IL-2, IL-4, IL-5, IL-10, IL-
13), or the combination of a panel of cytokines were assumed to be a helpful tool for the 
detection of drug hypersensitivity (12). 
The usefulness of such a cytokine panel containing IL-5 and in addition IL-2 or IFN-g has 
been described for extracellular cytokine detection (12, 17). 
6.3.3.2 Method selection 
The selection of the suitable method is also based on the objective of the study. Three 
different methods are generally accepted: 
i) ELISA 
The enzyme-linked immunosorbent assay is a suitable and generally accepted 
method to detect the presence and quantity of antigen in a sample (71, 72). 
ii) ELIspot 
The enzyme-linked immunosorbent spot is a modified version of the ELISA 
immunoassay and it allows visualization of the secretory product of individual 
activated or responding cells. Each spot that developed in the assay represents a 
single reactive cell. This provides both qualitative and quantitative (frequency of 
responding cells) information (46, 73, 74). 
iii) Flow cytometry 
Flow cytometry is a technique which allows simultaneous multiparametric analysis 
of the physical (granularity, size) and/or chemical characteristics (flurorescent 
dyes) of up to thousands of particles per second (50, 75, 76). 
 
The application of flow cytometry particulary the intracellular detection of cytokines was the 
new aspect of this study. Flow cytometry offered information about the T cell subpopulation 
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which is responsible for cytokine production. In contrast to flow cytometry studies which deal 
with secreted cytokines (12), new results could be obtained by this intracellular investigation. 
In addition, flow cytometry was combined with the ELISA test system which has been proven 
to be helpful in studies with similar scope (17). 
The ELIspot test system would have offered additional information about the T cell 
frequencies (77). Furthermore, a double staining would have been interesting to differentiate 
between T cells that secrete one or even more cytokines simultaneously. However,  
an additional evaluation of the ELIspot test system would have required a high amount of 
donor blood sample. 
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6.3.4 The LTT as methodical platform 
The overall study is based on a well-known method for the in vitro detection of drug 
hypersensitivities due to detection of T cell reactivity which has been demonstrated to be a 
reliable parameter. The LTT that served as methodical platform has been performed for the  
past 50 years or more. Most of the test concentrations used in this study were adopted from 
other studies dealing with optimal test concentrations in the LTT (15, 78, 79). 
The alternative of cytokine detection in cell culture supernatants using the LTT as methodical 
platform had been demonstrated before (17). By means of LTT, only the proliferation of  
T cells is detectable. 
However, drug-specific cytokine production and secretion are propounded in the course of 
proliferation events and they were supposed to be a more sensitive tool for the detection of 
drug hypersensitivities, due to the fact that a proliferation could be inhibited by regulatory 
mechanisms (Figure 9). 
 
¯
¯
¯
conventional  LTT
• Addition of 3H-thymidine for the last
   12-18 hours of incubation ® Staining of cell  surface (CD3, CD4, CD8)
• Detection of incorporated radioactivity ® Staining of cell  contents (IL-5, IFN-g, IL-10)
® Detection of secreted cytokines (IL-5, IFN-g, IL-2)
¯
Results demonstrate a proliferation.
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Figure 9. Conventional and modified LTT 
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This study is composed of two parts concerning the detection of T cell reactivity. In the pilot 
study a non-radioactive test system for the detection of drug hypersensitivities was established 
using flow cytometry and ELISA based on the detection of intra- and extracellular cytokines. 
In the following study this test system was applied with regard to selected clinical phenotype 
and a selected drug class. 
6.3.5 Pilot study 
In this study, determination of drug-specific cytokine production and secretion had been 
proven to be helpful for the detection of drug hypersensitivity. 
Based on a panel of cytokines investigated, sensitivities of about 50% for single cytokines but 
of 75% for the flow cytometry and 79% for the ELISA, were calculated respectively. 
However, when a panel of cytokines were tested in the ELISA and in the flow cytometry 
sensitivity increased to 100%. 
Concerning the TH1/TH2 dichotomy, Fernandez et al. (53) described that the expression of 
cytokines and cytokine receptors in both, skin biopsies and peripheral CD4+ T cells, were in 
accordance with a TH1 profile in patients with MPE. The in vitro data of the study conducted 
by the researcher concerning a preferential involvement of CD4+ and/or CD8 + T cells and the 
TH1/TH2 dichotomy appeared inconsistent and not in conformity with the following 
theoretical considerations or dogmas (Table 7). These inconsistencies, however, may be 
explained by differences in the individual test systems applied. In addition, quantitative 
differences of cytokines may not necessarily translate into qualitative differences since the 
biological activity of equal amounts may be different. Further on, it is unclear, if the 
intracellular cytokine detection pattern is representative for the overall (production/secretion) 
cytokine pattern. 
 
Overall this investigation suggests that the flow cytometry test system in combination with 
the ELISA test system is a helpful non-radioactive approach for the detection and 
characterization of drug hypersensitivities. It may provide a viable diagnostic alternative for 
instance in patients with a history of severe cutaneous drug reactions or life-threatening 
anaphylaxis where drug challenge testing is not recommendable. However, further studies 
comprising larger patient populations and a broader range of investigated substances are 
warranted to corroborate the findings of this study (27). 
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6.3.6 OSCS-contaminated heparins 
In the following part of the study in vitro cytokine patterns of patients with hypersensitivity 
reactions to contaminated heparin were compared with in vitro cytokine pattern of individuals 
with or without hypersensitivity to heparin, different glycosaminoglycans or other drugs, to 
elucidate the pathophysiology of the reactions. 
 
The incidents of reactions to contaminated heparins showed that it is important to identify the 
contaminations (the culprit antigen) and to identify the type of reaction, whether it is 
immunologic or non-immune-mediated. 
 
The culprit antigen was found (OSCS) but the pathomechanism was discussed and not fully 
understood yet (33, 34). In this study additional information based on T cell reactivity were 
added to the general view. 
The main clinically relevant finding was that PBMC from patients with hypersensitivity 
reactions to contaminated heparin secreted considerable amounts of IL-2 in vitro. This 
cytokine pattern differed from the other groups. 
Since most or all T cells produce IL-2 following antigen stimulation, secretion of IL-2 in 
PBMC from patients with OSCS-associated reactions is thus no proof for an antigen-specific 
T cell activation but may, to some extent, also reflect unspecific mechanisms. 
However, a completely unspecific reaction comparable with mitogen stimulation appeared 
unlikely given the in vitro non reactivity in control persons. 
 
The strong in vivo reactions could have been associated with T cells, but the in vitro type of 
reaction appears different from other allergic in vitro responses. 
In this respect, the markedly elevated rate of IL-2 secretion detected in the investigation, 
would also suggest an intolerance of further heparin applications, but all patients with 
reactions to contaminated heparin who were switched to non-contaminated heparin, tolerated 
these well. 
 
In a way GAG may have an exceptional position among all of our tested antigens since they 
are known to be immunmodulating substances. 
Effects of heparins on the immune system are demonstrated in this study by the results 
obtained with two patients who were currently treated with heparins. Secretion of cytokines 
was almost completely inhibited after stimulation with positive control (tetanus toxoid), but 
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was detected after stimulation with GAG. Hence, current heparin intake may be an interfering 
or even excluding criterion in investigations into lymphocyte reactivity in corresponding 
LTT-based test systems. 
In summary, immune-mediated hypersensitivity to heparins exhibited different in vitro 
findings than suspected non-immune-mediated hypersensitivity to heparins (36). 
6.3.7 Perspective 
Selected cytokine panel and method seemed to be suitable for the detection of drug 
hypersensitivity and gave additional information about the pathophysiology of the reactions. 
However, an optimal combination of cytokines and methods has not been described yet. 
The exact roles and function of cytokines have not been fully understood and “new” cytokines 
with a supposed key function in drug hypersensitivity are discovered all the time. Currently 
IL-17 is focussed concerning on its role in drug hypersensitivity (9). 
Further research must also be conducted to determine detailed correlations between the in 
vitro phenotypes and the in vivo phenotype. 
Although many questions concerning in vitro cytokine detection had to be answered cytokines 
will persist to be promising parameters for detection and characterization of drug 
hypersensitivity.
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7 Summary 
The LTT is the only in vitro test for detecting drug sensitization at the cellular level 
irrespective of the reaction’s phenotype. However, the LTT includes working with radioactive 
substances and is considered inappropriate for routine laboratory investigation. 
The aim of the pilot study was to assess drug-specific cytokine production by means of flow 
cytometry and ELISA as an alternative non-radioactive approach which may be more 
appropriate for routine testing and may provide more information about the pathophysiology 
of the reaction than proliferation-based assays. 
Patients with a suggestive history of drug hypersensitivity have been investigated. PBMC 
from patients and healthy control persons were incubated with the drugs of interest. CD4+ and 
CD8+ T cells were investigated by flow cytometry for intracellular IL-5, IFN-g and IL-10 
production. In addition, drug-specific secretion of IL-5, IL-2 and IFN-g were analyzed in the 
supernatants of the cultures by ELISA-techniques. 
Drug-specific cytokine production could be demonstrated in 74% of the patients using flow 
cytometry and in 79% using ELISA. Combining ELISA and flow cytometry increased the 
sensitivity to 100%. Investigation of typical TH1- and TH2-like cytokines (i.e. IL-5, IFN-g) 
allowed characterisation of the in vitro lymphocyte reactivity pattern. 
Analysis of drug hypersensitivity by means of flow cytometry proved a useful and reliable 
approach for the in vitro detection of drug hypersensitivities. Combining ELISA with flow 
cytometry further improved sensitivity. 
 
In the second part of the study drug-specific secretion of selected cytokines from PBMC of 
patients with hypersensitivity reactions to contaminated heparin were compared with the 
respective in vitro cytokine pattern of individuals with or without hypersensitivity to heparin, 
different glycosaminoglycans or other drugs.  
Study individuals (n=13) were classified as follows: Patients with hypersensitivity reactions 
to contaminated (OSCS) heparin (n=3), non-contaminated heparin (n=1), other compounds 
(n=4) and patients with ongoing heparin therapy without symptoms of intolerance (n=2). 
Three healthy individuals served as controls. PBMC were incubated with six different 
glycosaminoglycan structures. 
Drug-specific intracellular IL-5, IFN-g and IL-10 production was investigated by flow 
cytometry, whereas secretion of IL-5, IL-2 and IFN-g was analyzed by ELISA. 
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PBMC from individuals with hypersensitivity reactions to contaminated heparin secreted 
considerable amounts of IL-2 in vitro. There was a suggestion that ongoing heparin therapy 
and the Li-heparin in the vials may have impact on the PBMC's lymphocyte reactivity. 
The in vitro lymphocyte reactivity pattern of PBMC from individuals with hypersensitivity 
reactions to contaminated heparins was neither typical for an immune-mediated nor for a non-
immune-mediated reaction. Possible effects of heparins in the test system itself may require 
consideration. 
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